Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $41,800.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 836 shares of Pro-Dex stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $50.00, for a total transaction of $41,800.00. Following the transaction, the director now owns 278,109 shares of the company’s stock, valued at approximately $13,905,450. The trade was a 0.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Pro-Dex Stock Up 7.4 %

Shares of NASDAQ:PDEX opened at $55.19 on Thursday. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $179.97 million, a P/E ratio of 27.46 and a beta of 0.40. Pro-Dex, Inc. has a 52-week low of $16.84 and a 52-week high of $59.60. The stock’s fifty day simple moving average is $40.72 and its 200-day simple moving average is $40.53.

Pro-Dex (NASDAQ:PDEX) last released its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, equities research analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Institutional Trading of Pro-Dex

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp lifted its stake in shares of Pro-Dex by 14.1% during the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock worth $1,672,000 after purchasing an additional 4,426 shares during the period. Geode Capital Management LLC lifted its position in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares during the period. JPMorgan Chase & Co. boosted its stake in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the last quarter. EAM Investors LLC purchased a new stake in Pro-Dex in the 4th quarter valued at about $1,047,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in shares of Pro-Dex during the 4th quarter valued at about $995,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.